Tyzeka Novartis - Treatment for Chronic Hepatitis BTyzeka is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Posted: October 2006
- Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B - January 3, 2006
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.